North America Opioid Market Report

North America Opioid Market Analysis By Product (Immediate-release/Short-acting, Extended-release/Long-acting, Codeine, Oxycodone, Hydrocodone, Fentanyl, Morphine, Hydroxymorphone, Oxymorphone, Propoxyphene, Methadone, Tapentadol, Buprenorphine), By Application (Pain Relief, Cancer Pain, Post-operative Pain Management, Low Back Pain, Orthopedic, Anesthesia, Neuropathic Pain, Fibromyalgia, Cough Suppression, Diarrhoea Suppression, De-addiction) And Segment Forecasts To 2024

  • Published Date: Aug, 2016
  • Base Year for Estimate: 2015
  • Report ID: GVR-1-68038-075-0
  • Format: Electronic (PDF)
  • Historical Data: 2013-2015
  • Number of Pages: 80

Table of Content

Chapter 1 Research Methodology
                   1.1 Research Methodology
                   1.2 Research Scope & Assumptions
Chapter 2 Executive Summary
Chapter 3 Market Snapshot
Chapter 4 Market Variables, Trends & Scope
                   4.1 Market segmentation & scope
                      4.1.1 Market Driver Analysis
                            4.1.1.1 Expanding applications of opioids in various therapeutic conditions
                            4.1.1.2 Expanding target audience for the Opioid Market
                            4.1.1.3 Formulation of opioids switching from immediate to extended - release forms
                            4.1.1.4 Lack of control over opioid prescription abuse in Canada
                      4.1.2 Restraint analysis
                            4.1.2.1 Stringent regulatory framework
                            4.1.2.2 Opioid abuse and dependency
                   4.2 North America Opioid Market - SWOT Analysis, By Factor (political & legal, economic and technological)
                   4.3 Industry Analysis - Porter’s
Chapter 5 Market Categorization 1: Product Estimates & Trend Analysis
                   5.1 North America Opioid Market: Product movement analysis
                   5.2 Immediate - release / Short - acting opioids
                      5.2.1 Immediate - release / Short - acting opioid market, 2013 - 2024 (USD Million)
                      5.2.2 Codeine market, 2013 - 2024 (USD Million)
                      5.2.3 Oxycodone market, 2013 - 2024 (USD Million)
                      5.2.4 Hydrocodone market, 2013 - 2024 (USD Million)
                      5.2.5 Fentanyl market, 2012 - 2024 (USD Million)
                      5.2.6 Morphine market, 2013 - 2024 (USD Million)
                      5.2.7 Hydroxymorphone market, 2013 - 2024 (USD Million)
                      5.2.8 Oxymorphone market, 2013 - 2024 (USD Million)
                      5.2.9 Propoxyphene market, 2013 - 2024 (USD Million)
                      5.2.10 Other IR Opioid Market, 2013 - 2024 (USD Million)
                   5.3 Extended - release / Long - acting opioids
                      5.3.1 Extended - release / Long - acting Opioid Market, 2013 - 2024 (USD Million)
                      5.3.2 Oxycodone market, 2013 - 2024 (USD Million)
                      5.3.3 Hydrocodone market, 2013 - 2024 (USD Million)
                      5.3.4 Methadone market, 2013 - 2024 (USD Million)
                      5.3.5 Fentanyl market, 2013 - 2024 (USD Million)
                      5.3.6 Morphine market, 2013 - 2024 (USD Million)
                      5.3.7 Oxymorphone market, 2012 - 2024 (USD Million)
                      5.3.8 Tapentadol market, 2013 - 2024 (USD Million)
                      5.3.9 Buprenorphine market, 2013 - 2024 (USD Million)
                      5.3.10 Hydromorphone market, 2013 - 2024 (USD Million)
                      5.3.11 Others market, 2012 - 2024 (USD Million)
Chapter 6 Market Categorization 2: Application Estimates & Trend Analysis
                   6.1 Pain Relief
                      6.1.1 Pain relief market, 2013 - 2024 (USD Million)
                      6.1.2 Cancer pain market, 2013 - 2024 (USD Million)
                      6.1.3 Post - operative care market, 2013 - 2024 (USD Million)
                      6.1.4 Lower back pain market, 2012 - 2024 (USD Million)
                      6.1.5 Orthopedic market, 2013 - 2024 (USD Million)
                      6.1.6 Neuropathic market, 2013 - 2024 (USD Million)
                      6.1.7 Fibromyalgia market, 2013 - 2024 (USD Million)
                   6.2 Anesthesia
                      6.2.1 Anesthesia market, 2013 - 2024 (USD Million)
                   6.3 Cough Suppression
                      6.3.1 Cough Suppression, 2013 - 2024 (USD Million)
                   6.4 Diarrhea suppression
                   6.5 De - addiction
Chapter 7 Market Categorization 3: Regional Estimates & Trend Analysis, by Product & Application
                   7.1 North America Opioid Market share, by region, 2015 & 2024
                      7.1.1 North America Opioid Market, 2013 - 2024 (USD Million)
                      7.1.2 U.S. opioids market, 2013 - 2024 (USD Million)
                      7.1.3 Canada opioids market, 2013 - 2024 (USD Million)
Chapter 8 Competitive Landscape
                   8.1 Company Profiles
                      8.1.1 Purdue Pharma L.P.
                            8.1.1.1 Company Overview
                            8.1.1.2 Financial Performance
                            8.1.1.3 Product Benchmarking
                            8.1.1.4 Strategic Initiatives
                      8.1.2 Egalet Corporation
                            8.1.2.1 Company Overview
                            8.1.2.2 Financial Performance
                            8.1.2.3 Product Benchmarking
                            8.1.2.4 Strategic Initiatives
                      8.1.3 Janssen Pharmaceuticals, Inc.
                            8.1.3.1 Company Overview
                            8.1.3.2 Financial Performance
                            8.1.3.3 Product Benchmarking
                            8.1.3.4 Strategic Initiatives
                      8.1.4 West - Ward Pharmaceuticals Corporation
                            8.1.4.1 Company Overview
                            8.1.4.2 Financial Performance
                            8.1.4.3 Product Benchmarking
                            8.1.4.4 Strategic Initiatives
                      8.1.5 Pfizer,Inc.
                            8.1.5.1 Company Overview
                            8.1.5.2 Financial Performance
                            8.1.5.3 Product Benchmarking
                            8.1.5.4 Strategic Initiatives
                      8.1.6 Allergan Plc (Actavis)
                            8.1.6.1 Company Overview
                            8.1.6.2 Financial Performance
                            8.1.6.3 Product Benchmarking
                            8.1.6.4 Strategic Initiatives
                      8.1.7 Sanofi - Aventis S.A.
                            8.1.7.1 Company Overview
                            8.1.7.2 Financial Performance
                            8.1.7.3 Product Benchmarking
                            8.1.7.4 Strategic Initiatives
                      8.1.8 Sun Pharmaceutical Industries Limited
                            8.1.8.1 Company Overview
                            8.1.8.2 Financial Performance
                            8.1.8.3 Product Benchmarking
                            8.1.8.4 Strategic Initiatives


List of Tables

TABLE 1 North America Immediate - release(IR) Opioid Market: Drug information
TABLE 2 North America extended-release(ER) / long-acting Opioid Market: Drug Information
TABLE 3 North America Opioid Market, by product, 2013 - 2024 (USD Million)
TABLE 4 North America IR Opioid Market, by product, 2013 - 2024 (USD Million)
TABLE 5 North America ER Opioid Market, by product, 2013 - 2024 (USD Million)
TABLE 6 North America Opioid Market, by application, 2013 - 2024 (USD Million)
TABLE 7 North America pain relief Opioid Market, by application, 2013 - 2024 (USD Million)
TABLE 8 U.S. Opioid Market, by product, 2013 - 2024 (USD Million)
TABLE 9 U.S. IR Opioid Market, by product, 2013 - 2024 (USD Million)
TABLE 10 U.S. ER Opioid Market, by product, 2013 - 2024 (USD Million)
TABLE 11 U.S. Opioid Market, by application, 2013 - 2024 (USD Million)
TABLE 12 U.S. pain relief Opioid Market, by application, 2013 - 2024 (USD Million)
TABLE 13 Canada Opioid Market, by product, 2013 - 2024 (USD Million)
TABLE 14 Canada IR Opioid Market, by product, 2013 - 2024 (USD Million)
TABLE 15 Canada ER Opioid Market, by product, 2013 - 2024 (USD Million)
TABLE 16 Canada Opioid Market, by application, 2013 - 2024 (USD Million)
TABLE 17 Canada pain relief Opioid Market, by application, 2013 - 2024 (USD Million)


List of Figures

FIG. 1 Market summary, 2015 (USD million)
FIG. 2 Market trends & outlook
FIG. 3 Market segmentation & scope
FIG. 4 SWOT Analysis
FIG. 5 Porter’s Five Forces Analysis
FIG. 6 North America Immediate-release / Short-acting Opioid Market, 2012 - 2024 (USD Million)
FIG. 7 North America codeine market, 2013 - 2024 (USD Million)
FIG. 8 North America oxycodone market, 2013 - 2024 (USD Million)
FIG. 9 North America hydrocodone market, 2013 - 2024 (USD Million)
FIG. 10 North America fentanyl market, 2013 - 2024 (USD Million)
FIG. 11 North America morphine market, 2013 - 2024 (USD Million)
FIG. 12 North America hydroxymorphone market, 2013 - 2024 (USD Million)
FIG. 13 North America oxymorphone market, 2012 - 2024 (USD Million)
FIG. 14 North America propoxyphene market, 2013 - 2024 (USD Million)
FIG. 15 North America other IR Opioid Market, 2013 - 2024 (USD Million)
FIG. 16 North America extended-release / long-acting Opioid Market, 2013 - 2024 (USD Million)
FIG. 17 North America oxycodone market, 2013 - 2024 (USD Million)
FIG. 18 North America hydrocodone market, 2013 - 2024 (USD Million)
FIG. 19 North America methadone market, 2013 - 2024 (USD Million)
FIG. 20 North America fentanyl market, 2013 - 2024 (USD Million)
FIG. 21 North America morphine market, 2013 - 2024 (USD Million)
FIG. 22 North America oxymorphone market, 2013 - 2024 (USD Million)
FIG. 23 North America tapentadol market, 2013 - 2024 (USD Million)
FIG. 24 North America buprenorphine market, 2013 - 2024 (USD Million)
FIG. 25 North America hydromorphone market, 2013 - 2024 (USD Million)
FIG. 26 Other ER market, 2013 - 2024 (USD Million)
FIG. 27 Pain relief market, 2013 - 2024 (USD Million)
FIG. 28 Cancer pain market, 2013 - 2024 (USD Million)
FIG. 29 Postoperative pain management market, 2013 - 2024 (USD Million)
FIG. 30 Low back pain market, 2013 - 2024 (USD Million)
FIG. 31 Orthopedic market, 2013 - 2024 (USD Million)
FIG. 32 Neuropathic market, 2013 - 2024 (USD Million)
FIG. 33 Fibromyalgia market, 2013 - 2024 (USD Million)
FIG. 34 Anesthesia market, 2013 - 2024 (USD Million)
FIG. 35 Cough Suppression market, 2013 - 2024 (USD Million)
FIG. 36 Diarrhoea suppression market, 2013 - 2024 (USD Million)
FIG. 37 De-addiction market, 2013 - 2024 (USD Million)
FIG. 38 North America Opioid Market, 2013 - 2024 (USD Million)
FIG. 39 U.S. Opioid Market, 2013 - 2024 (USD Million)
FIG. 40 Canada pain reliever usage rates, 2009 - 2013 (Percentage)
FIG. 41 Canada Opioid Market, 2013 - 2024 (USD Million)

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.